Hubert A, Bonneau D, Couet D, Berthier M, Oriot D, Larrègue M
Unité de Génétique Médicale, Centre Hospitalier Universitaire de Poitiers, France.
Acta Paediatr. 1994 Jul;83(7):789-90. doi: 10.1111/j.1651-2227.1994.tb13143.x.
We report a newborn with isolated aplasia cutis congenita of the scalp whose mother was treated with valproic acid during pregnancy. Aplasia cutis congenita has been described in infants exposed in utero to antithyroid drugs, but has not been related to other tetratogenic agents. Fetal exposure to valproic acid is known to increase the risks of spina bifida and other midline defects. Interestingly, aplasia cutis congenita of the scalp is regarded as a cutaneous marker for neural dysraphism. However, this defect of the scalp and valproic acid intake during pregnancy may be a random association and similar observations are needed to suggest causality.
我们报告了一名患有孤立性先天性头皮皮肤发育不全的新生儿，其母亲在孕期接受了丙戊酸治疗。先天性皮肤发育不全在子宫内暴露于抗甲状腺药物的婴儿中已有描述，但尚未与其他致畸剂相关联。已知胎儿暴露于丙戊酸会增加脊柱裂和其他中线缺陷的风险。有趣的是，头皮先天性皮肤发育不全被视为神经管闭合不全的皮肤标志。然而，这种头皮缺陷与孕期丙戊酸摄入可能只是偶然关联，还需要更多类似观察来表明因果关系。
